Satsuma Pharmaceuticals, Inc.
STSADelisted Jun 8, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001692830
Satsuma Pharmaceuticals, Inc. was delisted on Jun 8, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 31 institutions reported holding it in 13F filings for Q1 2023, worth $12.7M in total; no superinvestor held it.
Holders of 5% or more of STSA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Satsuma Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Satsuma Pharmaceuticals, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
24 Schedule 13D and 13G filings on Satsuma Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 13, 2023 | BML Investment Partners, L.P. | 13G/AOld format | – | – | – | SEC |
| Jun 12, 2023 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Jun 8, 2023 | Shin Nippon Biomedical Laboratories, Ltd. | 13D/AOld format | – | – | – | SEC |
| May 2, 2023 | Growth Equity Opportunities 17, LLC | 13D/AOld format | – | – | – | SEC |
| Apr 18, 2023 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Apr 17, 2023 | Shin Nippon Biomedical Laboratories, Ltd. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Samlyn Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2023 | TPG GP A, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2023 | BML Investment Partners, L.P. | 13G/AOld format | – | – | – | SEC |
| Jan 27, 2023 | Growth Equity Opportunities 17, LLC | 13D/AOld format | – | – | – | SEC |
| Nov 16, 2022 | BML Investment Partners, L.P. | 13GOld format | – | New | – | SEC |
| Nov 16, 2022 | Commodore Capital LP | 13G/AOld format | – | – | – | SEC |
| Feb 25, 2022 | Samlyn Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Samlyn Capital, LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Commodore Capital LP | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | TPG GP A, LLC | 13G/AOld format | – | – | – | SEC |
| Oct 19, 2021 | Commodore Capital LP | 13G/AOld format | – | – | – | SEC |
| Apr 9, 2021 | Morgan Stanley | 13G/AOld format | – | – | – | SEC |
| Mar 31, 2021 | Shin Nippon Biomedical Laboratories, Ltd. | 13DOld format | – | New | – | SEC |
| Mar 15, 2021 | Growth Equity Opportunities 17, LLC | 13DOld format | – | New | – | SEC |
| Mar 15, 2021 | Commodore Capital LP | 13GOld format | – | New | – | SEC |
| Mar 2, 2021 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Citadel Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Morgan Stanley | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Satsuma Pharmaceuticals, Inc. shares.
No Form 144 notices for Satsuma Pharmaceuticals, Inc. are on file.